Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabazitaxel + midazolam
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination consists of **cabazitaxel**, a microtubule inhibitor approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel, and **midazolam**, a benzodiazepine primarily used for sedation, anxiolysis, and anesthesia. Cabazitaxel disrupts microtubule function, leading to cancer cell apoptosis. Midazolam acts as a positive allosteric modulator of the GABA-A receptor, enhancing inhibitory neurotransmission. Although cabazitaxel and midazolam can be co-administered clinically, there is no known therapeutic use for their fixed combination; their primary relevance is in drug-drug interaction studies where cabazitaxel exposure can increase when combined with midazolam due to CYP3A4 metabolism[1][2].
- Other names
- cabazitaxel + midazolam
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cabazitaxel + midazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabazitaxel + midazolam.